Andrew Joseph Muir, MD

Professor of Medicine
Chief, Division of Gastroenterology in the Department of Medicine
Member in the Duke Clinical Research Institute
Campus mail 03137B Hosp South, Durham, NC 27710
Phone (919) 684-2052
Email address andrew.muir@duke.edu
  • Hepatitis C 
  • Primary sclerosing cholangitis
  • Cirrhosis
  • Liver Transplantation
  • Clinical Trials
  • Healthcare disparities in liver disease 
  • Outcomes Research
In Their Words

Education and Training

  • Fellow In Gastroenterology, Medicine, Duke University, 1998 - 2000
  • Chief Medical Resident, Medicine, Duke University, 1997 - 1998
  • Fellow In Gastroenterology, Medicine, Duke University, 1996 - 1997
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.D., Duke University, 1993

Publications

Afdhal, N, Reddy, KR, Nelson, DR, Lawitz, E, Gordon, SC, Schiff, E, Nahass, R, Ghalib, R, Gitlin, N, Herring, R, Lalezari, J, Younes, ZH, Pockros, PJ, Di Bisceglie, AM, Arora, S, Subramanian, GM, Zhu, Y, Dvory-Sobol, H, Yang, JC, Pang, PS, Symonds, WT, McHutchison, JG, Muir, AJ, Sulkowski, M, Kwo, P, and ION-2 Investigators, . "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection." The New England journal of medicine 370, no. 16 (April 11, 2014): 1483-1493.

PMID
24725238
Full Text

Vierling, JM, Davis, M, Flamm, S, Gordon, SC, Lawitz, E, Yoshida, EM, Galati, J, Luketic, V, McCone, J, Jacobson, I, Marcellin, P, Muir, AJ, Poordad, F, Pedicone, LD, Albrecht, J, Brass, C, Howe, AYM, Colvard, LY, Helmond, FA, Deng, W, Treitel, M, Wahl, J, and Bronowicki, J-P. "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response." J Hepatol 60, no. 4 (April 2014): 748-756.

PMID
24362076
Full Text

Melia, MT, Bräu, N, Poordad, F, Lawitz, EJ, Shiffman, ML, McHutchison, JG, Muir, AJ, Galler, GW, Nyberg, LM, Lee, WM, Schiff, E, Long, J, Noviello, S, Brass, CA, Pedicone, LD, and Sulkowski, MS. "Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 58, no. 7 (April 2014): 960-969.

PMID
24399086
Full Text

Muir, AJ, Gong, L, Johnson, SG, Lee, MTM, Williams, MS, Klein, TE, Caudle, KE, and Nelson, DR. "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens." Clinical Pharmacology & Therapeutics 95, no. 2 (February 2014): 141-146.

Full Text

Muir, AJ, Gong, L, Johnson, SG, Lee, MTM, Williams, MS, Klein, TE, Caudle, KE, Nelson, DR, and Clinical Pharmacogenetics Implementation Consortium (CPIC), . "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens." Clin Pharmacol Ther 95, no. 2 (February 2014): 141-146.

PMID
24096968
Full Text

Vierling, JM, Davis, M, Flamm, S, Gordon, SC, Lawitz, E, Yoshida, EM, Galati, J, Luketic, V, McCone, J, Jacobson, I, Marcellin, P, Muir, AJ, Poordad, F, Pedicone, LD, Albrecht, J, Brass, C, Howe, AYM, Colvard, LY, Helmond, FA, Deng, W, Treitel, M, Wahl, J, and Bronowicki, JP. "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response." Journal of Hepatology 60, no. 4 (January 1, 2014): 748-756.

Full Text

Muir, AJ. "The rapid evolution of treatment strategies for hepatitis C." American Journal of Gastroenterology 109, no. 5 (January 1, 2014): 628-635. (Review)

Full Text

Muir, AJ, Arora, S, Everson, G, Flisiak, R, George, J, Ghalib, R, Gordon, SC, Gray, T, Greenbloom, S, Hassanein, T, Hillson, J, Horga, MA, Jacobson, IM, Jeffers, L, Kowdley, KV, Lawitz, E, Lueth, S, Rodriguez-Torres, M, Rustgi, V, Shemanski, L, Shiffman, ML, Srinivasan, S, Vargas, HE, Vierling, JM, Xu, D, Lopez-Talavera, JC, and Zeuzem, S. "A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection." Journal of Hepatology 61, no. 6 (January 1, 2014): 1238-1246.

Full Text

Thompson, A, Devine, S, Kattan, M, and Muir, A. "Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin." PloS one 9, no. 8 (January 2014): e103370-.

PMID
25084272
Full Text

Brown, CL, Hammill, BG, Qualls, LG, Curtis, LH, and Muir, AJ. "High morbidity and mortality in end-stage liver disease and heart failure." 2014.

Scholars@Duke

Pages